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 Abstract 
Dopamine-mediated neurotransmission plays an important role in relevant 
psychiatric and neurological disorders. Nowadays, there is an enormous interest in the 
development of new dopamine receptors (DR) acting drugs as potential new targets for 
the treatment of schizophrenia or Parkinson´s disease. Previous studies have revealed 
that isoquinoline compounds such as tetrahydroisoquinolines (THIQs) and 
tetrahydroprotoberberines (THPBs) can behave as selective D2 dopaminergic alkaloids 
since they share structural similarities with dopamine. In the present study we have 
synthesized eleven 2,3,9- and 2,3,11-trisubstituted THPB compounds (six of them are 
described for the first time) and evaluated their potential dopaminergic activity. Binding 
studies on rat striatal membranes were used to evaluate their affinity and selectivity 
towards D1 and D2 DR and establish the structure-activity relationship (SAR) as 
dopaminergic agents. In general, all the tested THPBs with protected phenolic hydroxyls 
showed a lower affinity for D1 and D2 DR than their corresponding homologues with 
free hydroxyl groups. In previous studies in which dopaminergic affinity of 1-benzyl-
THIQs (BTHIQs) was evaluated, the presence of a Cl into the A-ring resulted in 
increased affinity and selectivity towards D2 DR. This is in contrast with the current 
study since the existence of a chlorine atom into the A-ring of the THPBs caused 
increased affinity for D1 DR but dramatically reduced the selectivity for D2 DR. An OH 
group in position 9 of the THPB (9f) resulted in a higher affinity for DR than its 
homologue with an OH group in position 11 (9e) (250 fold for D2 DR). None of the 
compounds showed any cytotoxicity in freshly isolated human neutrophils. A molecular 
modeling study of three representative THPBs was carried out. The combination of MD 
simulations with DFT calculations provided a clear picture of the ligand binding 
interactions from a structural and energetic point of view. Therefore, it is likely that 
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 compound 9d (2,3,9-trihydroxy-THPB) behave as D2 DR agonist since serine residues 
cluster are crucial for agonist binding and receptor activation. 
 
Keywords: Tetrahydroprotoberberines, dopamine receptors, structure-activity 
relationships cytotoxicity, MTT and cytofluorometric analysis, theoretical calculations. 
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1. Introduction 
Dopamine-mediated neurotransmission plays an important role in several 
psychiatric and neurological disorders affecting several million people worldwide. 
Researchers have focused their efforts in investigating the modulation of dopaminergic 
activity via the dopamine receptors (DR) as potential targets for treating schizophrenia 
or Parkinson´s disease. Therefore, there is an increased interest in the discovery of novel 
dopaminergic ligands as potential drug candidates in the therapy of these neurological 
disorders [1]. DR can be classified into two pharmacologic families (D1 and D2-like) that 
are encoded by at least five genes. From a therapeutical point of view, drugs acting at 
D2-like DR are more relevant than those interacting with D1-like DR [2]. In this context, 
whereas the D2-like DR antagonists are used in the treatment of schizophrenia 
(antipsychotics), the agonists are used in the treatment of Parkinson’s disease [1,3]. In 
addition, other studies have revealed the potential role of D2 agonist in the treatment of 
depression. The pathophysiology of depression has been classically assigned to the 
noradrenaline and serotonine systems however, nowadays, published reports also 
support a role of the dopaminergic system in this disorder [2]. In regard to this, different 
selective D2-type DR agonists were found to display antidepressant-like actions in 
several rodent models, suggesting a specific role of this receptor subtype in their 
antidepressant efficacy [4-8].  
Previous studies from our group have revealed that isoquinoline compounds such 
as tetrahydroisoquinolines (THIQs) have affinity for DR in striate membranes of rat 
brain tissue which was likely due to their structural similarities to dopamine [8-18]. 
Likewise, tetrahydroprotoberberines (THPBs) are another group of natural and synthetic 
isoquinoline alkaloids with a variety of powerful biological activities, including 
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 dopaminergic activity [19-21]. Indeed, coreximine, a natural tetrasubstituted THPB, and 
other analogues were reported as selective D2 dopaminergic alkaloids [22]. Recently, l-
stepholidine analogues have been synthetized displaying a dual dopaminergic activity, 
partial agonism at the D1 DR and antagonism at D2 DR [23]. 
Since THPBs, THIQs and dopamine share structural similarities, in the present 
study we have synthesized eleven 2,3,9- and 2,3,11-trisubstituted THPB compounds (six 
of them are here described for the first time) and evaluated their potential dopaminergic 
activity. Their structures were determined on the basis of their NMR spectral data and 
mass spectrometry analysis. The structural features that define the affinity and 
selectivity of the three series of THPBs synthesized for D1/D2 receptors was determined 
analyzing the influence of the substitution at the 2,3- and 9 or 11 positions, in order to 
obtain dopaminergic ligands with increased specificity. Therefore, all the synthesized 
compounds were tested for their ability to displace the selective radioligands of D1 and 
D2-like DR from their specific binding sites in striatal membranes in order to establish 
the structure-activity relationship (SAR) as dopaminergic agents. In addition, 
cytotoxicity studies in human cells were carried out. For this purpose, we used the MTT 
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and a 
cytofluorometric analysis to determine their impact on human neutrophil apoptosis and 
survival [24-26]. All of them were devoid of any toxic effect in these in vitro assays.  
In order to better understand the molecular interactions stabilizing and 
destabilizing the different THPBs/D2DR complexes, a molecular modelling study using 
molecular dynamic simulations and quantum mechanic calculations was carried out for 
the most representative compounds of this series. Thus, the possible stereo-electronic 
requirements of the THPBs/D2 DR interactions have been discussed based on their 
different affinities. 
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 2. Results and Discussion  
In the present study, the impact of different substituents into the A- and D-ring of 
synthesized THPBs on dopaminergic affinity was evaluated. In previous reports, we 
determined the relevance of different substitutions into the A-ring in natural and 
synthetic isoquinoline alkaloids. We observed that the presence of hydroxyls groups in 
this ring caused increased affinity for the D1-like and D2-like DR families, while 
blockade of these hydroxyls groups resulted in decreased affinity [8,12-15]. Moreover, 
the presence of a halogen in the A-ring led to a selective binding at least to one of the 
two DR subtypes investigated [8,16,17]. Therefore, we have prepared three series of 
THPBs: 2,11-dihydroxy-3-chloro-THPB (series 1), 2,3-dihydroxy-11-methoxy-THPB 
(series 2) and 2,3,11-trihydroxy-THPB and 2,3,9-trihydroxy-THPB (series 3) and 
differently substituted analogues (Figure 1). 
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Figure 1. THPBs series. 
 
Inasmuch, at the concentrations tested none of the synthesized THPBs affected 
human neutrophil apoptosis or survival, indicating the absence of cytotoxicity for human 
cells in these in vitro approaches. Molecular modelling of the possible stereo-electronic 
requirements for dopamine D2 receptor ligands of the THPBs synthesized has been 
discussed based on the different affinities displayed. 
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 2.1. Chemistry 
The synthesis of the THPBs has been performed as outlined in the Schemes 1, 2 
and 3. The THPBs of the series 1 (Scheme 1) have been synthesized from 3-chloro-4-
methoxybenzaldehyde as starting material. 3-Chloro-4-methoxy-β-nitroestyrene was 
obtained from 3-chloro-4-methoxybenzaldehyde by a Henry’s reaction using 
nitromethane, ammonium acetate and acetic acid as solvent [27], and then, 3-chloro-4-
methoxyphenylethylamine (1) was obtained by reduction with lithium aluminum 
hydride [28]. This phenylethylamine (1), was treated with 3-methoxyphenylacetyl 
chloride under Schotten-Baumann conditions to generate the N-(3-cloro-4-
methoxyphenylethyl)-β-(3’-methoxyphenyl)acetamide (2) [29,30]. 
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Scheme 1. Synthesis of THPBs 3a and 3b (Series 1). Reagents and Conditions: (a) 
Nitromethane, NH4OAc, AcOH, reflux, 4h; (b) LiAlH4, THF / Et2O, N2, reflux, 2h; (c) CH2Cl2, 
3-methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (d) P2O5, POCl3, Toluene, N2, reflux, 8h; (e) 
NaBH4; MeOH, rt, 2h; (f) HCHO, EtOH, H2O, reflux, 5h; (g) CH2Cl2, BBr3, rt, 2h. 
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 Next, the phenylacetamide (2) was converted into the corresponding 1-
benzyltetrahydroisoquinoline (BTHIQ) (3) using the Bischler-Napieralski 
cyclodehydration reaction. The use of a POCl3 and P2O5 mixture in dry toluene followed 
by NaBH4 reduction was required since the presence of a halogen in position 3 of the 
phenylacetamide can inactivate the Bischler-Napieralski cyclodehydration reaction due 
to the electro-attractive properties of the halogen [8,31-33]. Once obtained, the BTHIQ 
6-chloro-7-methoxy-1-(3’-methoxybenzyl)-1,2,3,4-THIQ hydrochloride (3) was 
subjected to Mannich cyclization conditions using 37% aqueous formaldehyde [34] to 
generate the corresponding 2,11-dimethoxy-3-chloro-THPB (3a) with high yield (86%). 
Finally, the O-demethylation was performed by adding of 4 equivalents of BBr3 reagent 
for 2 hours at room temperature [8] to obtain the 2,11-dihydroxy-3-chloro-THPB (3b) 
(Scheme 1).  
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Scheme 2. Synthesis of THPBs 6a-6c (Series 2). Reagents and Conditions: (a) Benzyl chloride, 
K2CO3, EtOH, reflux, 6h; (b) Nitromethane, NH4OAc, AcOH, reflux, 4h; (c) LiAlH4, THF / 
Et2O, N2, reflux, 2h; (d) CH2Cl2, 3-methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (e) POCl3, 
 - 8 - 
 
 
 CH3CN, N2, reflux, 5h; (f) NaBH4; MeOH, rt, 2h; (g) 37% HCHO, EtOH, H2O, reflux, 5h; (h) 
EtOH-HCl, reflux, 3h; (i) DMF, CH2Cl2, CsF, reflux, 3h. 
 
The THPBs of the series 2 (Scheme 2) have been synthesized using similar 
approaches to those previously described. A protective reaction of the hydroxyl groups 
was performed in 3,4-dihydroxybenzaldehyde through dibenzylation [28]. Once 
prepared the protected 3,4-dibenzyloxybenzaldehyde, a similar sequence of synthesis 
steps were carried out to obtain the phenylethylamine (4), the phenylacetamide (5), the 
BTHIQ (6) and finally, the corresponding 2,3-dibenzyloxy-11-methoxy-THPB (6a) with 
good yields (63-93%). In this series, the Bischler-Napieralski cyclodehydration was 
performed using only POCl3 in dry acetonitrile since the presence of an alkoxy group in 
position 3 of the phenylacetamide can activate the Bischler-Napieralski 
cyclodehydration reaction due to the electro-donor ability of the oxygenated group. 
Then, this THPB was subjected to acidic conditions in absolute ethanol [12-35] in order 
to deprotect the phenolic hydroxyls groups yielding 2,3-dihydroxy-11-methoxy-THPB 
(6b). A methylendioxy group was generated by CsF and dichloromethane [13] from 6b 
to obtain the 2,3-methylendioxy-11-methoxy-THPB (6c). 
The THPBs of the series 3 (Scheme 3) have been synthesized employing similar 
procedures to those followed in series 1 and 2. The corresponding trisubstituted THPBs: 
2,3,11-trimethoxy-THPB (9a) and 2,3,9-trimethoxy-THPB (9b) were obtained from 3,4-
dimethoxyphenylethylamine (7). In this series, two different compounds were obtained 
based on the two possible positions of the Mannich cyclization. When cyclization was in 
para to the benzylic methoxy group, the 2,3,11-trimethoxy-THPB (9a) was the major 
product generated (77 % yield). In contrast, when cyclization occurred in ortho to the 
benzylic methoxy group then 2,3,9-trimethoxy-THPB (9b) was produced (8% yield). 
The phenolic hydroxyl groups were deprotected through O-demethylation conditions to 
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 obtain the corresponding 2,3,11-trihydroxy-THPB (9c) and 2,3,9-trihydroxy-THPB (9d) 
respectively. Finally, the THPBs with methylendioxy group were prepared as above 
described to generate 2,3-methylendioxy-11-hydroxy-THPB (9e) and 2,3-
methylendioxy-9-hydroxy-THPB (9f) respectively. 
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Scheme 3. Synthesis of THPBs 9a-9f (Series 3). Reagents and Conditions: (a) CH2Cl2, 3-
methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (b) POCl3, CH3CN, N2, reflux, 5h; and, 
NaBH4, MeOH, rt, 2h; (c) HCHO, EtOH, H2O, reflux, 5h; (d) CH2Cl2, BBr3, rt, 2h; (e) DMF, 
CH2Cl2, CsF, reflux, 3h. 
 
2.2. Binding affinities for dopamine receptors: Structure-activity relationship 
All the synthesized THPB compounds were assayed in vitro for their ability to 
displace the selective ligands of D1 and D2 DR from their respective specific binding 
sites in the striatal membranes. All the compounds except 6a, were able to displace [3H]-
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 SCH 23390 and [3H]-raclopride from their specific binding sites at micromolar (µM) or 
nanomolar (nM) concentrations. This was not surprising given the bulky substituents 
(Bn) at C3 and C4 in compound 6a. The binding affinities for D1 and D2 DR are 
summarized in Table 1 illustrating some general trends of the structure-activity 
relationship.  
Table 1 
Values of affinity (Ki, pKi) and selectivity (ratio Ki D1/Ki D2) determined in binding 
experiments to D1 and D2 DR of series 1-3. 
 
THPB 
Specific ligand D1 
[3H]-SCH 23390 
Specific ligand D2 
[3H]-raclopride Ki 
D1/D2 Ki (μM) m pKi m Ki (μM) m pKi m 
3a 3-Cl-2,11-diMeO 1.813 ± 0.146 5.76 ± 0.09 2.046 ± 0.347 5.70 ± 0.07 0.9 
3b 3-Cl-2,11-diOH 0.107 ± 0.004 6.97 ± 0.02
d,i 0.188 ± 0.021 6.73 ± 0.05b,i 0.6 
6a 2,3-diBnO-11-MeO 40.607 ± 4.215 4.39 ± 0.04
j 40.866 ± 1.461 4.38 ± 0.02j 1.0 
6b 2,3-diOH-11-MeO 1.108 ± 0.411 6.02 ± 0.17
e,h 0.078 ± 0.017 7.13 ± 0.09b,d,h 14.2 
6c 2,3-OCH2O-11-MeO 2.373 ± 1.208 5.77 ± 0.27
f 1.331 ± 0.536 5.94 ± 0.17l 1.8 
9a 2,3,11-triMeO 4.314 ± 0.703 5. 38 ± 0.07 8.543 ± 4.709 5.29 ± 0.36 0.5 
9b 2,3,9-triMeO 3.927 ± 0.908 5.44 ± 0.11 0.393 ± 0.115 6.44 ± 0.12b,c,k 10 
9c 2,3,11-triOH 2.962 ± 1.042 5.58 ± 0.15 0.396 ± 0.028 6.41 ± 0.03a 7.5 
9d 2,3,9-triOH 3.775 ± 0.992 5.46 ± 0.14 0.093 ± 0.024 7.07 ± 0.14b,d 40.6 
9e 2,3-OCH2O-11-OH 32.999 ± 5.009 4.49 ± 0.07
d 7.506 ±1.591 5.16 ± 0.09d 4.4 
9f 2,3-OCH2O- 9-OH 0.344 ± 0.027 6.47 ± 0.03
f,g 0.035 ± 0.012 7.55 ± 0.16a,f 10.0 
ANOVA, post Newmann-Keuls multiple comparison tests: 
a p < 0.05  b p < 0.01, vs D1-like DR.  
c p < 0.001 vs 9a.  d p < 0.001 vs 9c.  e p < 0.05 vs 9c. f p < 0.001 vs 9e. 
g p < 0.001 vs 9d.  h p < 0.001 vs 6a, 6c, 9a. i p < 0.001 vs 3a.  j p < 0.001 vs 6b. 
k p < 0.05 vs 9d.  l p < 0.01 vs 9e 
m Data were displayed as mean ± SEM for 3-5 experiments.  
 
 
2.2.1- Effect of the substituents into the A-ring of THPB 
a) In general, all the tested THPBs with protected phenolic hydroxyls showed a 
lower affinity for D1 and D2 DR than their corresponding homologues with free 
hydroxyl groups (see 3a vs 3b, 6a vs 6b, 9a vs 9c, 9b vs 9d in Table 1). The higher 
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 affinity for D1 and D2 DR of compounds with free phenolic group than those without 
was previously described albeit in several isoquinolines [8,12,16,21].  
b) In previous studies in which dopaminergic affinity of BTHIQs was evaluated, 
the presence of a chlorine atom into the A-ring (ortho of oxygenated group) resulted in 
increased affinity and selectivity towards D2 DR [8,16-18]. This is in contrast with the 
current study since the existence of a chlorine atom into the A-ring of the THPBs caused 
increased affinity for D1 DR but dramatically reduced the selectivity for D2 DR (see 3b 
vs 9c in Tabla 1). 
c) Our results also showed that the presence of a methylenedioxy group in 2,3 
position decreased the selectivity for D2 DR (see 6c vs 6b and 9e vs 9c in Table 1). This 
effect was also observed when the substituent into the D-ring was in position 9. In fact, 
when the dopaminergic affinities of THPB 9d (2,3,9-triOH) and 9f (2,3-OCH2O-, 9-OH) 
were compared, 9d exerted higher selectivity for D2 DR (Ki D1/D2 = 40.6) than 9f (Ki 
D1/D2 = 10). Moreover, the latter compound (9f) is the THPB displaying the highest 
affinity for both DR types (Ki = 344 nM for D1 and Ki = 35 nM for D2) (see Table 1 and 
Figure 2). 
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Figure 2. Displacement curves of [3H]-SCH 23390 (D1) and [3H] raclopride (D2) specific 
binding by compounds 9d and 9f. Data were displayed as mean ± SEM for 3-5 experiments. 
 
 
2.2.2- Effect of the 9 or 11 substituent into the D-ring of THPB 
The present study demonstrated that the affinity and the selectivity for DR 
depended on the position of the oxygenated substituents in positions 9 or 11 and on their 
protection or deprotection. In regard to this:  
a) A hydroxyl group in position 9 of the THPB (9f) resulted in a higher affinity for 
D1 and D2 DR than its homologue with a hydroxyl group in position 11 (9e). In this 
context, the affinity for D2 DR displayed by 9f was 214 fold higher than 9e (Table 1 and 
Figure 3). 
b) Surprisingly, either when this 2,3-methylenedioxy-11-OH-THPB (9e) was 
compared with the protected 2,3-methylenedioxy-11-OMe-THPB (6c), or when the 
2,3,11-triOH-THPB (9c) was compared with the protected 2,3-diOH-11-OMe-THPB 
(6b), an increased affinity for D1 and D2 DR was observed with the 11-O-protected 
derivatives (6c and 6b, see Table 1 and Figure 4). 
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Figure 3. Displacement curves of the specific binding of D1 and D2 DR ligands by the 
compounds 9e and 9f. Data were displayed as mean ± SEM for 3-5 experiments. 
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Figure 4. Displacement curves of the specific binding of D1 and D2 DR ligands by the 
compounds 6b and 9c. Data were displayed as mean ± SEM for 3-5 experiments. 
 
 
2.3. Cytotoxicity studies 
After determining the affinity for DRs of the synthesized THPBs, the potential 
cytotoxicity of these compounds was determined by the use of the MTT assay. The 
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 concentrations tested were selected based on their respective Ki value for D2 DR. None 
of the THPBs evaluated displayed any cytotoxicity on freshly isolated human 
neutrophils (Figure 5). 
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Figure 5. Effect of the synthesized THPBs on viability of human 
neutrophils. Data are presented as mean ± SEM of n=3 independent 
experiments. 
 
To confirm the absence of toxicity, we next investigated the effect on neutrophil 
apoptosis and survival of the most active THPBs on D2 DRs (6b, 9d and 9f). For this 
purpose a cytofluorimetric method was employed. As depicted in Figure 6 none of the 
THPBs at the concentrations assayed affected neutrophil apoptosis or survival indicating 
the lack of human cell toxicity of these compounds in this in vitro approach. 
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Figure 6. Percentage of apoptotic (A) and survival cells (B) after incubation with THPBs 6b, 9d 
and 9f. Early apoptotic cells were quantified as the percentage of total population of annexin 
V+,PI− cells, late apoptotic, and/or necrotic cells as annexin V+ and PI+, and viable 
nonapoptotic cells as annexin V− and PI− at 24 h of culture of human neutrophils. The columns 
are the means ± SEM of n=3 independent experiments. Representative flow cytometry panels 
showing the effects of compounds 6b, 9d and 9f on human neutrophil apoptosis have been 
included. 
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 2.4. Molecular modeling 
A molecular modeling study of three representative compounds of these series was 
performed to add further support to the results described in section 2.2. Special attention 
was paid to the effects exerted by the substituents into the D-ring of THPBs as well as to 
the increased affinity for the D2 DR detected by the 11-O-protected derivatives. 
Therefore, compounds 9d, 9c and 6b were selected for this comparative analysis due to 
their structural differences.  
First, MD calculations were carried out simulating the molecular interactions 
between compounds 9d, 9c and 6b with the human D2 DR (Figure 7). In general, the 
three compounds displayed their pharmacophoric portions in a closely related spatial 
form to that reported for dopamine [17,18]. Consistent with previous experimental [36] 
and theoretical [37] data, the simulation indicated the relevance of the negatively 
charged aspartate 114 (D114) for ligand binding. In this contex, the highly conserved 
D114 in trans-membrane helix 3 (TM3) is important for both D2 DR agonists and 
antagonists binding [36,38], and its terminal carboxyl group may function as an 
anchoring point for ligands with protonated amino groups [39-41]. In the current study, 
all the compounds simulated were docked into the receptor with the protonated amino 
group close to D114. Although after 5 ns of MD simulations the ligands slightly moved 
in a way different from the initial position, the strong interaction with D114 was 
maintained for all the complexes (see Figure 7), reinforcing the role of the amino acid 
as an anchoring point for ligands with protonated amino groups.  
Next, the relative energies (∆∆G values) obtained for the different complexes were 
analysed. A 0.00, 12.14 and 2.58 Kcal/mol for complexes 9d/D2DR, 9c/D2DR and 
6b/D2DR, respectively were obtained. These binding energies (BE) were in agreement 
with the experimental data (see Ki values in Table 1). However, although BE allowed to 
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 differentiate between very good and weak binders (0.00 kcal/mol for compound 9d vs 
12.14 kcal/mol for compound 9c), those with similar binding affinities did not (0.0 
kcal/mol for compound 9d vs 2.58 kcal/mol for compound 6b). This was not surprising 
since MD simulations poorly approximate features that might be playing determinant 
roles such as lone pair directionality in hydrogen bonds, explicit π∙∙∙π stacking 
polarization effects, hydrogen bonding networks, induced fit, and conformational 
entropy. Collectively, the information obtained from MD simulations might explain in 
part the differential D2 DR affinity displayed by compounds 9d and 9c.  
To acquire more detailed insights into the mechanisms driving the binding of the 
THPBs to the D2 DR active site, the structure-affinity relationship was further analysed. 
The THPB-residue interaction spectra calculated by the free energy decomposition 
suggested that the interaction spectra of compounds 9d, 9c and 6b with D2 DR was 
closely related. Nevertheless, some subtle but significant differences were detected 
reflecting differential binding features (Figure 8). 
In this regard, it is interesting to note that the only structural difference between 
compounds 9d and 9c is the position of the OH groups in the D ring (see Scheme 3). 
Despite of it, a significant difference was obtained for their respective calculated BE, 
indicating that 9d/D2DR complex was markedly more stable than 9c/D2DR. The 
comparison of both spectra (Figures 8a and 8b) revealed that the OH group of 
compound 9d at position 9 (Figure 8a) was forming a strong hydrogen bond interaction 
with Y416. This is a particularly strong stabilizing interaction which is due to the acidic 
character of the oxygen atom of the Tyr residue. In contrast, the OH group of 9c/D2DR 
complex (Figure 8b), was located within a hydrophobic pocket where only weak 
hydrogen bonds (O….H-C with the side chains of the amino acids) can take place (see 
the weak stabilizing interaction with Y416, Figure 8b). In addition, although the 
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 complex of compound 9c displayed a moderated interaction with S193, there was not a 
stabilizing interaction with S197. This is in sharp contrast with 9d spectra since two 
strong interactions with S193 and Ser197 were encountered (Figure 8a). 
The remainder of the amino acids stabilizing these complexes (D114, V111 V115, 
C118, C182, I183, I184 W382, H393, F389, F390 and T412) exerted closelly related 
interactions. In ligth of these observations, it is tempting to speculate that the different 
stabilizing interactions of complexes 9d/D2 DR and 9c/D2DR could explain both the 
different ∆∆G values and the experimental affinities (Table 1). 
On the other hand, when the activities of the 2,3,11-triOH-THPB (9c) and the 
protected 2,3-diOH-11-OMe-THPB (6b) were compared, an increased affinity for D2 
DR was exerted by the 11-O-protected derivative (Table 1). The analysis of the two 
spectra (Figure 8b and 8c) showed that compound 6b can establish two strong 
molecular interactions with two serine residues (S193 and S197). The average structures 
obtained for the complexes 9d/ D2DR, 9c/D2DR, and 6b/D2DR from the last ns of 
simulation are shown in Figures 9a, 9b and 9c, respectively. The salt bridge between 
the protonated N-H group of BTHPs and the carboxyl group of D114 as well as the rest 
of the interactions previously discussed can be appreciated in this figure.  
At this stage, the trend predicted for the MD simulations can be considered as 
certainly significant. However, it should be noted that we were dealing with relatively 
weak interactions and therefore MD simulations might underestimate such interactions. 
Therefore, reduced models were constructed to perform more accurate DFT calculations 
(B3LYP/6-·1G(d)). These calculations allowed to perform a QTAIM analysis for a 
further characterization of the most critical interactions for these ligands.  
The main interactions of compound 9d at the binding pocket and the interactions 
net obtained are illustrated in Figure 10. The OH-2 in the catecholic ring is acting as a 
 - 19 - 
 
 
 proton donor with S193 (ρ(rb)=0.0207 au) and as a proton acceptor with two amino 
acids, H393 (0.0187 au) and S194 (0.0012 au). The OH-3 behaves as a proton donor 
with S197 (0.0238 au) and is also involved in three weak C-H hydrogen bonds with 
S193, S194 and V115. The OH-9 possesses only one strong hydrogen bond with Y416 
(0.0370 au). It is noteworthy that the hydrogen bonds between the catecholic hydroxyls 
(OH-2 and OH-3) with the serine residues (S193 and S194) are facilitated by the 
adequate spatial orientation of the molecule in which the atoms of rings A, B, C and D 
are making further interactions with other residues (Figure 10). These stabilizing 
interactions include the strong salt bridge between the ammonium group of 9d with the 
carboxyl group of D114, the weaker C-H--S interaction with S118 and the C-H--π 
interactions with F389 and V115. These interactions are present with varying intensity 
in the three compounds here analyzed.  
The main interactions of compound 9c at the binding pocket are shown in Figure 
11. To facilitate the description of the molecule interactions, this figure was divided in 
two and the interactions of the catecholic ring are illustrated in Figure 11a. The OH-2 
establishes a hydrogen bond with the carbonyl oxygen of the backbone of S193 (0.0246 
au) but not with the side chain oxygen as found for 9d/D2DR. It also acts as a proton 
acceptor with H393 (0.0147 au) and with a C-H bond of the side chain of S193 (0.0067 
au). The OH-3 behaves as a proton acceptor for C-H interactions with F390 and V115 
without proton donor activity with any residue except a very weak H--H contact with 
S197 (0.0016 au). In addition, this OH can establish two O--O interactions with the 
carbonyl oxygen at S193 and the hydroxyl at S197. Such interactions suggest that this 
hydroxyl group is weakly bond at the binding site compared with 9d/D2DR complex. In 
fact, while the sum of electronic density of all OH-3 interactions in the binding site 
(∑ρ (rb)) is 0.0247 for compound 9c, the value for compound 9d was 0.0391 au. The 
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 OH-11 is forming C-H--O type interactions with C182 (0.0031 au), I183 (0.0037 au) and 
F110 (0.0022 au), O--O type interactions with the carbonyl oxygen of backbone C182 
(0.0044 au) and a weak H--H interaction with V91 (0.0019 au) (Figure 11b).  
Figure 12 shows the main interactions of compound 6b at the binding pocket. The 
interaction pattern of this compound shares similarities with those observed for 
compound 9d. In fact, OH-2 and OH-3 are acting as proton donors with S193 (0.0340 
au) and S197 (0.0308 au) and as proton acceptors with H393 (0.0064 au), I184 (0.0048 
au), S193 (0.0114 au) and V115 (0.0065 au) (Figure 12a). OMe-11 is only forming two 
very weak hydrogen bonds with the C-H bonds of the side chain (ρ(rb) = 0.0015) and 
the backbone (0.0011au) of I183 (Figure 12b).The CH3 group is interacting with C182 
(C-H--S interaction (0.0039 au)), V91 (C-H interaction (0.0085 au)) as well as with 
F110 (H--H interaction (ρ(rb) = 0.0184 au). Taken together all these observations and 
the sum of the electronic density of all the interactions (0.0150 au), it can be concluded 
that the binding strength of OMe-11 to D2DR is not relevant. In contrast, compound 6b 
interactions seemed to be stronger when they are established between the catecholic 
hydroxyls and the serine residues. As oppose to the OH-11 of 9c who remained almost 
fixed with the same orientation (Figure 11b), the OMe-11 group in 6b is rotating almost 
freely during the simulation for MD calculations. This is a striking observation which 
may account for 9c and 6b differential D2DR affinitiesy. Finally, the QTAIM analysis 
seem to indicate that the increased affinities of compounds 9d and 6b compared with 
those of 9c may rely on the stronger interactions established between the catecholic 
hydroxyls and the serine residues. 
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3. Conclusions 
In summary, we have synthesized several THPBs with different substituents into 
their A- and D- rings and evaluated the SAR for their potential dopaminergic affinity. 
Three series of THPBs were obtained: 2,11-dihydroxy-3-chloro-THPBs (series 1), 2,3-
dihydroxy-11-methoxy-THPBs (series 2) and 2,3,11-trihydroxy-THPBs and 2,3,9-
trihydroxy-THPBs (series 3). Concerning to their affinity for DR: first, the presence of 
hydroxyls groups into the A-ring resulted in increased the DR affinity and, blockade of 
these groups blunted these responses; second, a halogen in the A-ring shifted the 
selectivity of the compound towards one of the DR investigated; third, while the 
presence of an OH at position 9 resulted in a positive effect on DR affinities, its 
localization at position 11 was surprisingly detrimental, and the blockade of this 
hydroxyl group at position 11 (MeO) reversed their DR affinity.  
In addition, none of the compounds evaluated showed any cytotoxicity in freshly 
isolated human neutrophils. Finally, a molecular modeling study of three representative 
THPBs was carried out. The QTAIM analysis allowed a further understanding of the 
different experimental affinities obtained for compounds 9d, 9c and 6b. Since serine 
residues cluster seemed to be crucial for agonist binding and receptor activation, it is 
likely that compounds 9d and 6b displayed such capability.  
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Figure 7. Spatial view of compound 9d (green)/D2DR interaction. Magnification of the receptor 
active site at the right. 
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Figure 8. Histograms of interaction energies partitioned for D2 DR amino acids when 
complexed with compound 9d (a), compound 9c (b) and compound 6b (c). The x-axis denotes 
the residue number of D2 DR, and the y-axis shows the interaction energy between the 
compound and the specific residue. Negative and positive values represent favourable or 
unfavourable binding, respectively. 
a 
b 
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Figure 9. Spatial view of the active D2 DR site for compounds 9d (a), 9c (b) and 6b (c).  
The names of the residues involved in the main interactions are written in the figure. 
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Figure 10. Molecular graph of compound 9d interaction with the binding site. Large spheres 
represent attractors or nuclear critical points (3, -3) attributed to the atomic nuclei. The 
connecting nuclei lines are bond paths and small spheres on them are bond critical points (3, -1). 
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Figure 11. Molecular graph of compound 9c interaction with the binding site. The interactions 
for the catecholic hydroxyls are shown in (a) and the interactions of OH-11 are shown in (b). 
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Figure 12. Molecular graph for compound 6b interaction at the binding site. The interactions for 
the catecholic hydroxyls are shown in (a) and the interactions of OMe-11 are shown in (b). 
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4. Experimental Section 
 
4.1. General Instrumentation  
EIMS and FAB mass were recorded on a VG Auto Spec Fisons spectrometer 
instruments (Fisons, Manchester, United Kingdom). 1H NMR and 13C NMR spectra 
were recorded with CDCl3 or C5D5N as a solvent on a Bruker AC-300, AC-400 or AC-
500. Multiplicities of 13C NMR resonances were assigned by DEPT experiments. 
COSY, HSQC and HMBC correlations were recorded at 400 MHz and 500 MHz 
(Bruker AC-400 o AC-500). The assignments of all compounds were made by COSY, 
DEPT, HSQC and HMBC. All the reactions were monitored by analytical TLC by silica 
gel 60 F254 (Merck 5554). Residues were purified by sílica gel 60 (40-63 µm, Merck 
9385) column chromatography. Solvents and reagents used were purchased from 
commercial sources. Quoted yields are of purified material. The HCl salts of the 
synthesized compounds were prepared from the corresponding base with 5% HCl in 
MeOH.  
4.2. Chemistry  
4.2.1. General procedure for the synthesis of phenyethylamines (1 and 4). 
4.2.1.1. 3,4-Dibenzyloxybenzaldehyde. A mixture of 3,4-dihydroxybenzaldehyde 
(1 g, 7.24 mmol), benzyl chloride (3 mL, 24.51 mmol) and anhydrous K2CO3 (2.1 g, 
14.3 mmol) in absolute EtOH (15 mL) was refluxed for 6 h. After being stirred, the 
reaction mixture was concentrated to dryness, redissolved in 10 mL of CH2Cl2, and then 
5% aqueous NaOH (3 x 10 mL) was added. The combined organic layers were dried 
over with anhydrous Na2SO4 and evaporated to dryness. The residue obtained was 
purified by silica gel column chromatography (Hexane/EtOAc, 8:2) to obtain the 3,4-
dibenzyloxybenzaldehyde (1.5 g, 65%) as a white solid. 1H NMR (500 MHz, CDCl3): 
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 δ= 9.83 (s, 1H, CHO), 7.56 (m, 2H, H-2, H-6), 7.48-7.27 (m, 10H, 2 x Ph), 7.02 (d, J= 
13.7 Hz, 1H, H-5), 5.22 (s, 2H, PhCH2O-3), 5.17 (s, 2H, PhCH2O-4); 13C NMR (125 
MHz, CDCl3) δ= 191.2 (CHO), 155.7 (C-4), 150.6 (C-3), 136.5 (C-1′), 136.3 (C-1′′), 
130.5 (C-1), 129-127 (6C, C-2′-4′ y C-2′′-4′′), 124.6 (CH-6), 116.9 (CH-5), 115.7 (CH-
2), 71.3 (PhCH2O-3), 71.1 (PhCH2O-4); ESMS m/z (%): 341 [M+Na]+, 313 (100).  
4.2.1.2. 3-Chloro-4-methoxy-β-nitrostyrene. A mixture of 3-chloro-4-methoxy-
benzaldehyde (1 g, 5.87 mmol), nitromethane (1 mL, 18.41 mmol) and NH4OAc (1.2 g, 
15.57 mmol) in AcOH (15 mL) was refluxed for 4 h. After this time, the reaction 
mixture was cooled to room temperature, diluted with H2O (10 mL), and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layer were washed with brine (2 x 10 mL) 
and H2O (2 x 10 mL), dried over with anhydrous Na2SO4, and evaporated to dryness to 
obtain the 3-chloro-4-methoxy-β-nitrostyrene (1.1 g, 88%) as yellow needles, which was 
used in the following step with no further purification. 1H NMR (400 MHz, CDCl3): δ= 
7.91 (d, J= 13.7 Hz, 1H, H-β), 7.59 (d, J= 2.2 Hz, 1H, H-2), 7.52 (d, J= 13.7 Hz, 1H, H-
α), 7.44 (dd, J= 8.6, 2.2 Hz, 1H, H-6), 6.97 (d, J= 8.6 Hz, 1H, H-5), 3.90 (s, 3H, OCH3-
4);  13C NMR (100 MHz, CDCl3) δ 158.4 (C-4), 138.4 (CH-β), 136.4 (CH-α), 130.9 
(CH-2), 130.1 (CH-6), 124.2 (C-1), 123.7 (C-3), 112.7 (CH-5), 56.8 (OCH3-4); MS (EI) 
m/z (%): 213 (55) [M]+, 185 (100).  
4.2.1.3. 3,4-Dibenzyloxy-β-nitrostyrene. 3,4-dibenzyloxybenzaldehyde (1 g, 3.15 
mmol) was subjected to similar conditions to those above described to obtain the 3,4-
dibenzyloxy-β-nitrostyrene (1.70 g, 99%) as yellow needles, which was used in the 
following step with no further purification. 1H NMR (500 MHz, CDCl3): δ= 7.81 (d, J= 
13.6 Hz, 1H, H-β), 7.36 (d, J= 13.6 Hz, 1H, H-α), 7.38-7.23 (m, 10H, 2 x Ph), 7.01 (dd, 
J= 8.3, 2.1 Hz, 1H, H-6), 6.99 (d, J= 2.1 Hz, 1H, H-2), 6.87 (d, J= 8.3 Hz, 1H, H-5), 
5.15 (s, 2H, PhCH2O-3), 5.10 (s, 2H, PhCH2O-4); 13C NMR (125 MHz, CDCl3) δ= 
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 152.7 (C-4), 149.1 (C-3), 139.1 (CH-β), 136.4 (C-1′), 136.2 (C-1′′), 135.3 (CH-
α), 129−127 (6C, C-2′-4′ y C-2′′-4′′), 124.7 (CH-6), 123.1 (C-1), 114.3 (CH-2), 114.2 
(CH-5), 71.4 (PhCH2O-4), 70.8 (PhCH2O-3); ESMS m/z (%): 362 (100) [M+H]+.  
4.2.1.4. β-(3-Chloro-4-methoxyphenyl)ethylamine (1). A solution of 3-chloro-4-
methoxy-β-nitrostyrene (1 g, 4.7 mmol) in anhydrous THF (14 mL) was added dropwise 
to a well-stirred suspension of LiAlH4 (0.7 g, 18.5 mmol) in anhydrous Et2O (20 mL) 
under nitrogen atmosphere, and refluxed for 2 h. Then the reaction mixture was cooled 
and the excess reagent was destroyed by a dropwise addition of H2O (2 mL) and 15% 
aqueous NaOH (5 mL). After a partial evaporation of the filtered portion, the aqueous 
solution was extracted with CH2Cl2 (3 x 10 mL) and the organic layer was extracted 
with 5% aqueous HCl (3 x 10 mL). The resulting aqueous acid layer was made basic 
(5% aqueous NH4OH to achieve pH ≈ 9) and extracted with CH2Cl2 (3 x 10 mL). The 
organic layers were washed with brine (2 x 10 mL) and H2O (2 x 10 mL), dried over 
with anhydrous Na2SO4 and concentrated to dryness to obtain the β-(3-chloro-4-
methoxyphenyl)ethylamine (1) (630 mg, 72%) as a yellow oil. 1H NMR (500 MHz, 
CDCl3): δ= 7.33 (d, J= 2.2 Hz, 1H, H-2), 7.21 (dd, J= 8.5, 2.2 Hz, 1H, H-6), 6.88 (d, J= 
8.5 Hz, 1H, H-5), 3.89 (s, 3H, OCH3-4), 2.96 (m, 2H, H-β), 2.67 (m, 2H, H-α); 13C 
NMR (125 MHz, CDCl3): δ= 153.8 (C-4), 133.3 (C-1), 130.8 (CH-2), 128.4 (CH-
6), 122.6 (C-3), 112.5 (CH-5), 56.5 (OCH3-4), 43.8 (CH2-β), 39.1 (CH2-α); MS (EI) m/z 
(%): 185 (45) [M]+. 
4.2.1.5. β-(3,4-Dibenzyloxy-phenyl)ethylamine (4). 3,4-dibenzyloxy-β-
nitrostyrene (1.70 g, 4.7 mmol) was subjected to similar conditions to those above 
described to obtain the β-(3,4-dibenzyloxyphenyl)ethylamine (4) (1.44 g, 93%) as a 
yellow oil. 1H NMR (500 MHz, CDCl3): δ= 7.47 (m, 4H, H-2′, H-6′ y H-2′′, H-6′′), 7.38 
(m, 6H, H-3′, H-5′ y H-3′′, H-5′′), 6.83-6.76 (m, 3H, H-2, H-5, H-6), 5.16 (s, 2H, 
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 PhCH2O-3), 5.15 (s, 2H, PhCH2O-4), 2.98 (m, 2H, CH2-β), 2.83 (m, 2H, CH2-α); 13C 
NMR (125 MHz, CDCl3): δ= 149.7 (C-3), 147.0 (C-4), 136.7 (C-1′), 136.6 (C-1′′), 130.8 
(C-1), 128.9-127.1 (6C, C-2′, C-4′ y C-2′′,C-4′′), 122.1 (CH-6), 112.8 (CH-2), 112.3 
(CH-5), 121.9 (CH-6), 116.0 (CH-2), 112.8 (CH-4), 71.3 (PhCH2O-4), 71.2 (PhCH2O-
3), 41.9 (CH2-β), 39.3 (CH2-α); ESMS m/z (%): 333 (100) [M+H]+.  
4.2.2. General procedure for the synthesis of acetamides (2, 5 and 8) under 
Schotten-Baumann conditions.  
Formation of acetamides was carried out under Schotten-Baumann conditions 
using the appropriate phenylethylamine and the corresponding acid chloride. 
4.2.2.1. N-(3-chloro-4-methoxyphenylethyl)-β-(3’-methoxyphenyl)acetamide 
(2). An amount of 0.3 mL of 2-(3-methoxyphenyl)acetyl chloride (2.55 mmol) was 
added dropwise at 0 ºC to a solution of β-(3-chloro-4-methoxyphenyl)ethylamine (1) 
(500 mg, 2.69 mmol) in CH2Cl2 (20 mL) and 5% aqueous NaOH (4.4 mL) with stirring 
at room temperature for 3 h. After the mixture was stirred, 2.5% aqueous HCl was added 
and the organic solution was washed with brine (2 x 10 mL) and H2O (2 x 10 mL), dried 
over with anhydrous Na2SO4 and evaporated to dryness. The residue obtained was 
purified by sílica gel column chromatography (Hexane/CH2Cl2/EtOAc, 20:70:10) to 
afford the acetamide (2) (378 mg, 45%) as a white oil. 1H NMR (500 MHz, CDCl3): δ= 
7.15 (t, J= 9.5 Hz, 1H, H-5′), 6.98 (d, J= 2.1 Hz, 1H, H-2), 6.74 (dd, J= 8.4, 2.1 Hz, 1H, 
H-6), 6.70 (dd, J= 9.5, 3.3 Hz, 1H, H-4′), 6.68 (m, 1H, H-5), 6.65 (m, 1H, H-6′), 6.62 (t, 
J= 3.3 Hz, 1H, H-2′), 5.50 (m, 1H, NH),  3.77 (s, 3H, OCH3-4), 3.68 (s, 3H, OCH3-3′), 
3.33 (s, 2H, CH2-CO), 3.31 (dd, J= 12.9, 6.8 Hz, 2H, H-α), 2.55 (t, J= 6.8 Hz, 2H, H-β); 
13C NMR (125 MHz, CDCl3): δ= 170.7 (CO), 159.9 (C-3′), 153.5 (C-4), 136.1 (C-1′), 
131.7 (C-1), 130.4 (CH-2), 130.0 (CH-5′), 127.9 (CH-6), 122.2 (C-3), 121.6 (CH-
6′), 114.9 (CH-2′), 112.8 (CH-4′), 112.1 (CH-5), 56.1 (OCH3-4), 55.1 (OCH3-3′), 43.8 
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 (CH2-CO), 40.6 (CH2-α), 34.3 (CH2-β); MS (FAB) m/z (%): 356 [M+Na]+, 186 (85), 
169 (100).  
4.2.2.2. N-(3,4-Dibenzyloxyphenylethyl)-β-(3’-methoxyphenyl)acetamide (5). 
β-(3,4-dibenzyloxyphenyl)ethylamine (500 mg, 1.5 mmol) was subjected to similar 
conditions to those above described  to obtain the N-(3,4-dibenzyloxyphenylethyl)-β-(3’-
methoxyphenyl)acetamide (5). The residue was purified by silica gel column 
chromatography (Hexane/CH2Cl2/ EtOAc, 20:70:10), to obtain the acetamide 5 (450 mg, 
63%) as a white oil. 1H NMR (500 MHz, CDCl3): δ= 7.45-7.30 (m, 10H, Ph-3 y Ph-4), 
7.20 (t, J= 8.0 Hz, 1H, H-5′), 6.80 (m, 1H, H-5), 6.80 (m, 1H, H-6′), 6.78 (m, 1H, H-2′), 
6.72 (m, 1H, H-2), 6.72 (m, 1H, H-4′), 6.52 (dd, J= 8.1, 1.9 Hz, 1H, H-6), 5.43 (m, 1H, 
NH),  5.13 (s, 2H, PhCH2O-4), 5.10 (s, 2H, PhCH2O-3), 3.75 (s, 3H, OCH3-3′), 3.47 (s, 
2H, NHCOCH2), 3.39 (q, J= 6.7 Hz, 2H, H-α), 2.63 (t, J= 6.7 Hz, 2H, H-β); 13C NMR 
(125 MHz, CDCl3): δ= 170.6 (CO), 159.9 (C-3′), 149.0 (C-3), 147.6 (C-4), 137.4 (C-
1′′′), 137.2 (C-1′′), 136.2 (C-1′), 132.0 (C-1), 129.9 (CH-5′), 128.5-127.3 (10CH, Ph-3 y 
Ph-4), 121.6 (CH-6), 121.5 (CH-2′), 114.9 (CH-2), 114.9 (CH-4′), 112.8 (CH-5), 112.8 
(CH-6′), 71.4 (PhCH2O-4), 71.3 (PhCH2O-3), 55.1 (OCH3-3′), 43.8 (NHCOCH2),  40.6 
(CH2-α), 34.8 (CH2-β); MS (FAB) m/z (%): 504 [M+Na]+, 413 (55), 322 (100).  
4.2.2.3. N-(3,4-Dimethoxyphenylethyl)-β-(3’-methoxyphenyl)acetamide (8). 
3,4-dimethoxy-phenylethylamine (500 mg, 2.79 mmol) was subjected to similar 
conditions to those above described to obtain the N-(3,4-dimethoxyphenylethyl)-β-(3’-
methoxyphenyl)acetamide (8). The residue was purified by silica gel column 
chromatography (Hexane/CH2Cl2/ EtOAc, 20:70:10), to obtain the acetamide 8 (2 g, 
91%) as a white oil. 1H NMR (500 MHz, CDCl3): δ= 7.21 (dd, J= 8.3, 7.9 Hz, 1H, H-5′), 
6.80 (dd, J= 8.3, 1.9 Hz, 1H, H-4′), 6.73 (d, J= 7.9 Hz, 1H, H-6′), 6.72 (m, 1H, H-2′), 
6.70 (d, J= 8.1 Hz, 1H, H-2), 6.60 (d, J= 1.9 Hz, 1H, H-5), 6.53 (dd, J= 8.1, 1.9 Hz, 1H, 
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 H-6), 5.44 (m, 1H, NH), 3.85 (s, 3H, OCH3-4), 3.81 (s, 3H, OCH3-3), 3.76 (s, 3H, 
OCH3-3′), 3.49 (s, 2H, NHCOCH2), 3.43 (dd, J= 12.8, 6.8 Hz, 2H, H-α), 2.67 (t, J= 6.8 
Hz, 2H, H-β); 13C NMR (125 MHz, CDCl3): δ= 170.7 (CO), 159.9 (C-3′), 148.9 (C-3), 
147.6 (C-4), 136.2 (C-1′), 131.1 (C-1), 129.9 (CH-5′), 121.6 (CH-6′), 120.5 (CH-
6), 114.9 (CH-2), 112.8 (CH-2′), 111.7 (C-4′), 111.2 (CH-5), 55.8 (OCH3-4), 55.7 
(OCH3-3), 55.1 (OCH3-3′), 43.9 (COCH2), 40.7 (CH2-α), 34.9 (CH2-β); MS (FAB) m/z 
(%): 330 [M+H]+ , 182 (45), 165 (100).  
4.2.3. Synthesis of 1,2,3,4-tetrahydroisoquinoleines (3, 6 and 9) by Bischler-
Napieralski cyclisation.  
4.2.3.1. 6-Chloro-7-methoxy-1-(3’-methoxybenzyl)-1,2,3,4-THIQ (3). The 
acetamide 2 (300 mg, 0.93 mmol) was added in dry toluene (10 mL) to a 100 mL three-
neck round-bottom flask at 0 ºC under N2 and treated with P2O5 (4.2 g, 15.02 mmol), 
which was added in portions and followed by the dropwise addition of POCl3 (1.37 mL, 
15.02 mmol). The mixture was stirred and refluxed under N2 for 6 h, and then cooled to 
room temperature. Toluene was concentrated under reduced pressure and the reaction 
mixture was slowly poured into a mixture of crushed ice. The solid residue was 
triturated with 20 % aqueous NaOH to obtain a suspension (pH ≈ 8-9) and then 
extracted with CH2Cl2 (3 x 15 mL). The combined CH2Cl2 extracts were dried over 
Na2SO4 and the solvent was evaporated in vacuo obtaining a reddish oil. The residue 
was dissolved in MeOH (10 mL), cooled to -78 ºC and then treated with NaBH4 (76 mg, 
2 mmol). The reaction mixture was stirred for 2 h.  Thereafter, H2O (15 mL) was added 
and volatiles were evaporated under reduced pressure. The aqueous phase was extracted 
with CH2Cl2 (3 x 15 mL), and the combined organic layers were dried over with 
anhydrous Na2SO4 and evaporated to dryness. The crude product was purified by silica 
gel column chromatography (CH2Cl2/MeOH, 95:5) to furnish 6-chloro-7-methoxy-1-(3’-
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 methoxybenzyl)-1,2,3,4-THIQ (3) (155 mg, 54%) as a yellow oil. Then, the 3 
hydrochloride salt was prepared for use in the next reaction. 1H NMR (500 MHz, 
CDCl3) for the free base form: δ= 7.25 (t, J= 7.5 Hz, 1H, H-5′), 7.10 (s, 1H, H-5), 6.83 
(d, J= 7.5 Hz, 1H, H-6′), 6.80 (m, 1H, H-4′), 6.79 (m, 1H, H-2′), 6.64 (s, 1H, H-8), 4.18 
(dd, J= 9.2, 4.7 Hz, 1H, H-1), 3.80 (s, 3H, OCH3-7), 3.77 (s, 3H, OCH3-3′), 3.17-2.92 
(m, 4H, H-3 y CH2-α), 2.71 (m, 2H, H-4); 13C NMR (125 MHz, CDCl3): δ= 159.8 (C-
3′), 152.7 (C-7), 140.2 (C-1′), 137.8 (C-8a), 130.5 (CH-5), 129.6 (CH-5′), 128.2 (C-4a), 
121.7 (CH-6′), 120.3 (C-6), 115.1 (CH-2′), 111.9 (CH-4′), 110.1 (CH-8), 56.9 (CH-1), 
56.1 (OCH3-7), 55.1 (OCH3-3′), 42.6 (CH2-α), 40.2 (CH2-3),  28.7 (CH2-4); MS (FAB) 
m/z (%): 318 [M+H]+, 196 (100). 
4.2.4. General procedure for the synthesis of 1,2,3,4-tetrahydroisoquinoleines 
(6 and 9) by Bischler-Napieralski cyclisation.  
4.2.4.1. 6,7-Dibenzyloxy-1-(3’-methoxybenzyl)-1,2,3,4-THIQ (6). The 
corresponding acetamide 5 (300 mg, 0.645 mmol) was added in dry acetonitrile (20 mL) 
to a 100 mL three-neck round-bottom flask at 0 ºC under N2,  and treated with POCl3 
(0.45 mL, 4.5 mmol). The mixture was stirred and refluxed under N2 for 5 h and then 
cooled to room temperature. Acetonitrile was concentrated under reduced pressure and 
the reaction mixture was slowly poured into a mixture of crushed ice. The solid residue 
was triturated with 10% aqueous NaOH to obtain a suspension (pH ≈ 8-9) which was 
then extracted with CH2Cl2 (3 x 15 mL). The combined CH2Cl2 extracts were dried over 
Na2SO4 and the solvent was evaporated in vacuo obtaining a reddish oil. The residue 
was dissolved in MeOH (10 mL), cooled to -78 ºC and then treated with NaBH4 (76 mg, 
2 mmol). The reaction mixture was stirred for 2 h. Next, H2O (15 mL) was added and 
volatiles were evaporated under reduced pressure. The aqueous phase was extracted with 
CH2Cl2 (3 x 15 mL), and the combined organic layers were dried over Na2SO4 and 
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 evaporated to dryness. The crude product was purified by silica gel column 
chromatography (CH2Cl2/MeOH, 95:5) to furnish THIQ (6) (180 mg, 63%) as a yellow 
oil. Then, the 6 hydrochloride salt was prepared for use in the next reaction. 1H NMR 
(500 MHz, CDCl3) for the free base form: δ= 7.45-7.30 (m, 10H, Ph-4 y Ph-3), 7.26 (m, 
1H, H-5′), 6.81 (m, 1H, H-6′), 6.83 (m, 2H, H-2′, H-4′), 6.77 (s, 1H, H-5), 6.71 (s, 1H, 
H-8), 5.15 (s, 2H, PhCH2O-4), 5.11 (s, 2H, PhCH2O-3), 4.11 (dd, J= 9.5, 4.2 Hz, 1H, H-
1), 3.81 (s, 3H, OCH3-3′), 3.18 (m, 1H, H-3α), 3.10 (dd, J= 13.6, 4.2 Hz, 1H, H-α′), 2.91 
(m, 1H, H-3β), 2.85 (dd, J= 13.6, 9.5 Hz, 1H, H-α′′), 2.73 (m, 1H, H-4α), 2.69 (m, 1H, 
H-4β); 13C NMR (125 MHz, CDCl3): δ= 159.7 (C-3′), 147.6 (C-7), 146.8 (C-6), 140.6 
(C-1′), 137.5 (C-1′′), 137.4 (C-1′′′), 131.4 (C-8a), 129.6 (CH-5′), 128.4-127.3 (10CH, 
Ph-6 y Ph-7), 127.9 (C-4a), 121.7 (CH-6′), 115.5 (CH-4′), 115.0 (CH-5), 113.9 (CH-
2′), 111.8 (CH-8), 71.8 (PhCH2O-7), 71.3 (PhCH2O-6), 56.7 (CH-1), 55.1 (OCH3-3′), 
42.6 (CH2-α), 40.7 (CH2-3), 34.8 (CH2-4); MS (FAB) m/z (%): 466 [M+H]+, 344 (100).  
4.2.4.2. 6,7-Dimethoxy-1-(3’-methoxybenzyl)-1,2,3,4-THIQ (9). N-(3,4-
dimethoxy-phenyl-ethyl)-β-(3’-methoxyphenyl)acetamide (300 mg, 0.91 mmol) was 
subjected to similar conditions to those above described to obtain the 6,7-dimethoxy-1-
(3’-methoxybenzyl)-1,2,3,4-THIQ (9). The residue was purified by silica gel column 
chromatography (CH2Cl2/ MeOH, 95:5), to afford the THIQ (9) (264 mg, 93%), as a 
yellow oil. Then, the 9 hydrochloride salt was prepared for use in the next reaction. 1H 
NMR (500 MHz, CDCl3) for the free base form: δ= 7.23 (dd, J= 7.6 Hz, 1H, H-5′), 6.83 
(d, J= 7.6 Hz 1H, H-6′), 6.79 (m, 1H, H-2′), 6.77 (m, 1H, H-4′), 6.58 (s, 1H, H-5), 6.53 
(s, 1H, H-8), 4.22 (dd, J= 8.5, 5.2 Hz, 1H, H-1), 3.84 (s, 3H, OCH3-6), 3.77 (s, 3H, 
OCH3-3′), 3.76 (s, 3H, OCH3-7), 3.18 (dt, J= 12.0, 5.9 Hz 1H, H-3α), 3.16 (dd, J= 12.7, 
5.2 Hz, 1H, H-α′), 2.99 (dd, J= 12.7, 8.5 Hz 1H, H-3β), 2.96 (m, 1H, H-α′′), 2.78 (m, 
2H, H-4); 13C NMR (125 MHz, CDCl3): δ= 159.7 (C-3′), 147.6 (C-6), 147.0 (C-7), 
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 140.1 (C-1′), 129.6 (CH-5′), 129.2 (C-8a), 126.6 (C-4a), 121.7 (CH-6′), 115.1 (CH-2′), 
111.9 (CH-5), 111.7 (CH-4′), 109.5 (CH-8), 56.5 (CH-1), 55.8 (OCH3-3′), 55.8 (OCH3-
7), 55.1 (OCH3-6), 42.5 (CH2-α), 40.3 (CH2-3), 28.7 (CH2-4); MS (FAB) m/z (%): 314 
[M+H]+, 192 (100).  
4.2.5. General procedure for the synthesis of tetrahydroprotoberberines (3a, 
6a, 9a and 9b) by Mannich cyclisation.  
4.2.5.1. 2,11-Dimethoxy-3-chlorotetrahydroprotoberberine (3a). The 
corresponding THIQ 3 (100 mg, 0.313 mmol) hydrochloride was added to a MeOH/ 
HCl 37% (20:1) (pH 1-4) solution placed in a 100 mL round-bottom flask and then 
evaporated to dryness. The compound was then dissolved in absolute ethanol (2 mL), 
H2O (3 mL) and 37% aqueous formaldehyde (3 mL) and stirred and refluxed for 5 h. 
Thereafter, the reaction mixture was concentrated to dryness. The residue was basified 
with a 5% aqueous NaOH and the aqueous layer was extracted with CH2Cl2 (3 x 15 
mL). The combined organic layers were dried over with anhydrous Na2SO4 and 
concentrated to dryness. The crude product was purified by silica gel column 
chromatography (Hexane/CH2Cl2/EtOAc, 20:70:10) to obtain THPB (3a) (85.4 mg, 0.26 
mmol, 86%). 1H NMR (500 MHz, CDCl3): δ= 7.14 (s, 1H, H-4), 7.00 (d, J= 8.4 Hz, 1H, 
H-9), 6.75 (s, 1H, H-1), 6.73 (dd, J= 8.4, 2.5 Hz, 1H, H-10), 6.70 (d, J= 2.5 Hz, 1H, H-
12), 3.98 (d, J= 14.5 Hz, 1H, H-8α), 3.91 (s, 3H, OCH3-2), 3.79 (s, 3H, OCH3-11), 3.70 
(d, J= 14.5 Hz, 1H, H-8β), 3.64 (dd, J= 11.4, 3.6 Hz, 1H, H-14),  3.29 (dd, J= 16.2, 3.6 
Hz, 1H, H-13α), 3.15 (m, 1H, H-6α), 3.10 (m, 1H, H-5α), 2.93 (dd, J= 16.2, 11.4 Hz, 
1H, H-13β), 2.67 (m, 1H, H-5β), 2.60 (m, 1H, H-6β); 13C NMR (125 MHz, CDCl3): δ= 
158.1 (C-11), 153.2 (C-2), 137.2 (C-14a), 135.1 (C-12a), 130.1 (CH-4),  127.7 (C-
4a), 127.1 (CH-9), 126.3 (C-8a), 120.5 (C-3), 113.2 (CH-12), 112.4 (CH-10), 109.2 
(CH-1), 59.5 (CH-14), 57.8 (CH2-8), 56.3 (OCH3-2), 55.2 (OCH3-11), 50.9 (CH2-6), 
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 36.7 (CH2-13), 28.3 (CH2-5); MS (FAB) m/z (%): 330 [M+H]+, 196 (100); HRMS-FAB 
[M+H] + calcd for C19H21NO2Cl: 330.1255, found: 330.1262. 
4.2.5.2. 2,3-Dibenzyloxy-11-methoxytetrahydroprotoberberine (6a). 6,7-
dibenzyloxy-1-(3’-methoxybenzyl)-1,2,3,4-THIQ (6) (100 mg, 0.215 mmol) 
hydrochloride was subjected to similar conditions to those above described to obtain the 
2,3-dibenzyloxy-11-methoxy-THPB (6a). The residue was purified by silica gel column 
chromatography (CH2Cl2/ MeOH, 99:1), to obtain THPB 6a (93 mg, 93%) as a yellow 
oil. 1H NMR (500 MHz, CDCl3): δ= 7.45-7.30 (m, 10H, Ph-2 y Ph-3), 6.99 (d, J= 8.4 
Hz, 1H, H-9), 6.83 (s, 1H, H-1), 6.75 (m, 1H, H-10), 6.72 (s, 1H, H-4), 6.68 (m, 1H, H-
12), 5.16 (s, 2H, PhCH2O-2), 5.12 (s, 2H, PhCH2O-3), 3.95 (d, J= 14.4 Hz, 1H, H-8α), 
3.79 (s, 3H, OCH3-11), 3.63 (d, J= 14.4 Hz, 1H, H-8β), 3.53 (dd, J= 11.2, 3.5 Hz, 1H, 
H-14), 3.17 (dd, J= 16.3, 3.5 Hz, 1H, H-13α), 3.13 (m, 1H, H-6α), 3.10 (m, 1H, H-5α), 
2.82 (dd, J= 16.3, 11.2 Hz, 1H, H-13β), 2.60 (m, 1H, H-5β), 2.58 (m, 1H, H-6β); 13C 
NMR (125 MHz, CDCl3): δ= 157.9 (C-11), 147.7 (C-2), 147.2 (C-3), 137.4 (C-1′′′), 
137.2 (C-1′′), 135.5 (C-12a), 130.6 (C-14a), 128.4-127.3 (8 x CH-Ph, CH-9), 127.0 (C-
4a), 126.7 (C-8a), 114.9 (CH-4), 113.4 (CH-10), 113.2 (CH-1), 112.1 (CH-12), 72.2 
(PhCH2O-3), 71.1 (PhCH2O-2), 59.4 (CH-14), 58.1 (CΗ2-8), 55.2 (OCH3-11), 51.4 
(CH2-6), 36.9 (CH2-13), 28.9 (CH2-5); MS (FAB) m/z (%): 478 [M+H]+, 344 (100). 
HRMS-FAB [M+H] + calcd for C32H32NO3: 478.2377, found: 478.2389. 
4.2.5.3. 2,3,11-Trimethoxytetrahydroprotoberberine (9a) and 2,3,9-
trimethoxy-tetrahydroprotoberberine (9b)  by Mannich cyclisation. 6,7-dimethoxy-
1-(3’-methoxybenzyl)-1,2,3,4-THIQ (9) (100 mg, 0.32 mmol) hydrochloride was 
subjected to similar conditions to those above described to obtain the 2,3,11-trimethoxy-
THPB (9a) and 2,3,9-trimethoxy-THPB (9b). In this case, both compounds were 
obtained as a consequence the two possible cyclization positions: in para position to the 
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 methoxyl group (THPB 9a, major product) or in ortho position (THPB 9b, minor 
product).  
4.2.5.4. 2,3,11-Trimethoxytetrahydroprotoberberine (9a) was purified by silica 
gel column chromatography (Hexane/ EtOAc, 50:50, to obtain 9a as a white oil (76 mg, 
77%). 1H NMR (500 MHz, CDCl3): δ= 7.00 (d, J= 8.3 Hz, 1H, H-9), 6.74 (s, 1H, H-1), 
6.72 (m, 1H, H-10), 6.70 (m, 1H, H-12), 6.62 (s, 1H, H-4), 3.97 (d, J= 14.5 Hz, 1H, H-
8α), 3.89 (s, 3H, OCH3-2), 3.86 (s, 3H, OCH3-3), 3.78 (s, 3H, OCH3-11), 3.66 (d, J= 
14.5 Hz, 1H, H-8β), 3.58 (dd, J= 11.3, 3.5 Hz, 1H, H-14), 3.29 (dd, J= 16.2, 3.4 Hz, 1H, 
H-13α), 3.15 (m, 1H, H-6α), 3.15 (m, 1H, H-5α), 2.88 (dd, J= 16.2, 11.3 Hz, 1H, H-
13β), 2.65 (m, 1H, H-5β), 2.60 (m, 1H, H-6β); 13C NMR (125 MHz, CDCl3): δ= 157.9 
(C-11), 147.4 (C-2), 147.4 (C-3), 135.5 (C-12a), 129.6 (C-14a), 127.1 (CH-9), 126.7 (C-
4a), 126.6 (C-8a), 113.2 (CH-12), 112.3 (CH-10), 111.3 (CH-4), 108.6 (CH-1), 
59.5 (CH-14), 58.1 (CΗ2-8), 56.0 (OCH3-2), 55.8 (OCH3-3), 55.2 (OCH3-11), 51.4 
(CH2-6), 37.1 (CH2-13), 29.0 (CH2-5); MS (FAB) m/z (%): 326 [M+H]+ , 192 (100). 
HRMS-FAB [M+H] + calcd for C20H24NO3: 326.1751, found: 326.1750. 
4.2.5.5. 2,3,9-Trimethoxytetrahydroprotoberberine (9b) was purified by silica 
gel column chromatography (Hexane/ EtOAc, 50:50), to obtain 9b as a yellow oil (8 mg, 
0.0246 mmol, 8%). 1H NMR (500 MHz, CDCl3): δ= 7.15 (t, J= 7.9 Hz, 1H, H-11), 6.79 
(d, J= 7.9 Hz, 1H, H-12), 6.75 (s, 1H, H-1), 6.70 (d, J= 7.9 Hz, 1H, H-10), 6.62 (s, 1H, 
H-4), 4.20 (d, J= 15.8 Hz, 1H, H-8α), 3.89 (s, 3H, OCH3-2), 3.87 (s, 3H, OCH3-3), 3.83 
(s, 3H, OCH3-9), 3.60 (dd, J= 11.1, 3.1 Hz, 1H, H-14), 3.46 (d, J= 15.8 Hz, 1H, H-8β), 
3.30 (dd, J= 16.1, 3.1 Hz, 1H, H-13α), 3.20 (m, 1H, H-6α), 3.15 (m, 1H, H-5α), 2.90 
(dd, J= 16.1, 11.1 Hz, 1H, H-13β), 2.65 (m, 1H, H-5β), 2.65 (m, 1H, H-6β); 13C NMR 
(125 MHz, CDCl3): δ= 155.8 (C-9), 147.4 (C-2), 147.4 (C-3), 135.8 (C-12a), 129.7 (C-
14a), 126.8 (C-4a), 126.7 (CH-11), 123.4 (C-8a), 120.8 (CH-12), 111.4 (CH-4), 108.6 
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 (CH-1), 107.1 (CH-10), 58.9 (CH-14), 56.0 (OCH3-2), 55.8 (OCH3-3), 55.2 (OCH3-9), 
53.7 (CΗ2-8), 51.4 (CH2-6), 36.9 (CH2-13), 29.1 (CH2-5); MS (FAB) m/z (%): 326 
[M+H]+, 192 (100); HRMS-FAB [M+H] + calcd for C20H24NO3: 326.1751, found: 
326.1754. 
4.2.6. General procedure for the synthesis of THP 3b, 9c and 9d by O-
demethylation.  
4.2.6.1. 2,11-Dihydroxy-3-chloro-tetrahydroprotoberberine (3b). A solution of 
the appropriate THPB (3a) (50 mg, 0.15 mmol) in dry CH2Cl2 (5 mL) was cooled to -78 
ºC. Then, BBr3 (0.4 mL, 1.02 mmol) was dropwise added to the stirring solution. After 
15 min, the reaction mixture was left to warm up to room temperature and stirred for 2 
h. The reaction was terminated by the dropwise addition of MeOH (1 mL) and the 
mixture was further stirred for another 30 min. The solvent was concentrated to dryness. 
The crude product was purified by silica gel column chromatography (CH2Cl2:MeOH, 
90:10), to obtain THPB (3b) (37 mg, 75%) as a yellow oil. 1H NMR (500 MHz, C5D5N) 
δ= 7.22 (s, 1H, H-1), 7.18 (s, 1H, H-4), 7.05 (m, 1H, H-10), 7.03 (m, 1H, H-9), 6.96 (m, 
1H, H-12), 3.99 (d, J= 14.3 Hz, 1H, H-8α), 3.61 (m, 1H, H-8β), 3.56 (m, 1H, H-14), 
3.26 (dd, J= 16.1, 3.5 Hz, 1H, H-13α), 3.12 (m, 1H, H-5α), 3.06 (m, 1H, H-6α), 2.98 
(dd, J= 16.1, 11.6 Hz, 1H, H-13β), 2.60 (m, 1H, H-5β), 2.52 (m, 1H, H-6β); 13C NMR 
(125 MHz, C5D5N): δ= 157.1 (C-11), 152.6 (C-2), 138.1 (CH-14a), 135.9 (C-12a 8a), 
130.0 (CH-4), 127.3 (CH-9), 126.7 (C-4a), 125.1 (C-12a), 119.6 (C-3), 115.7 (CH-12), 
114.8 (CH-1), 114.4 (CH-10), 59.5 (CH-14), 57.9 (CH2-8), 51.4 (CH2-6), 36.9 (CH2-13), 
28.3 (CH2-5); MS (FAB) m/z (%): 302 [M+H]+, 182 (100); HRMS-FAB [M+H] + calcd 
for C17H17NO2Cl: 302.0942, found: 302.0946. 
4.2.6.2. 2,3,11-Trihydroxy-tetrahydroprotoberberine (9c). 2,3,11-trimethoxy-
THPB (9a) (50 mg, 0.15 mmol) was subjected to similar conditions to those above 
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 described to obtain the 2,3,11-trihydroxy-THPB (9c). The same equivalents of BBr3 
were employed despite the presence of increased methoxyl group numbers. The residue 
was purified by silica gel column chromatography (CH2Cl2/ MeOH, 90:10), to obtain the 
THPB 9c (43 mg, 99%) as a white oil. 1H NMR (500 MHz, C5D5N): δ= 7.15 (s, 1H, H-
1), 7.01 (m, 1H, H-9), 7.00 (s, 3H, OH), 6.99 (m, 1H, H-12), 6.96 (s, 1H, H-4), 6.92 (m, 
1H, H-10), 4.26 (d, J= 14.5 Hz, 1H, H-8α), 3.99 (d, J= 10.8 Hz, 1H, H-14), 3.91 (d, J= 
14.5 Hz, 1H, H-8β), 3.37 (m, 1H, H-13α), 3.33 (m, 1H, H-5α), 3.32 (m, 1H, H-6α), 3.14 
(m, 1H, H-13β), 2.89 (m, 1H, H-6β), 2.71 (m, 1H, H-5β); 13C NMR (125 MHz, C5D5N): 
δ= 157.6 (C-11), 146.2 (C-2), 145.9 (C-3), 135.1 (C-12a), 127.5 (C-14a), 127.5 (CH-9), 
124.5 (C-8a), 122.9 (C-4a), 116.1 (CH-4), 115.7 (CH-10), 114.7 (CH-12), 113.5 (CH-1), 
59.7 (CH-14), 57.2 (CH-8), 51.4 (CH2-6), 36.1 (CH2-13), 27.8 (CH2-5); MS (FAB) m/z 
(%): 284 [M+H]+, 164 (100); HRMS-FAB [M+H] + calcd for C17H18NO3: 284.1281, 
found: 284.1284. 
4.2.6.3. 2,3,9-Trihydroxytetrahydroprotoberberine (9d). 2,3,9-trimethoxy-
THPB (9b) (50 mg, 0.15 mmol) was subjected to similar conditions to those above 
described to obtain the 2,3,9-trihydroxy-THPB (9d). The residue was purified by silica 
gel column chromatography (CH2Cl2/ MeOH, 90:10), to obtain the THPB 9d (42 mg, 
97%) as a grey oil. 1H NMR (500 MHz, C5D5N): δ= 7.21 (s, 1H, H-1), 7.11 (t, J= 7.8 
Hz, 1H, H-11), 6.97 (s, 1H, H-4), 6.94 (d, J= 7.8 Hz, 1H, H-10), 6.71 (d, J= 7.8 Hz, 1H, 
H-12), 6.00 (s, 3H, OH), 4.71 (d, J= 15.7 Hz, 1H, H-8α), 3.97 (dd, J= 11.3, 3.4 Hz, 1H, 
H-14), 3.92 (d, J= 15.7 Hz, 1H, H-8β), 3.42 (dd, J= 16.4, 3.4 Hz, 1H, H-13α), 3.38 (m, 
1H, H-5α), 3.36 (m, 1H, H-6α), 3.28 (dd, J= 16.4, 11.3 Hz, 1H, H-13β), 2.87 (m, 1H, H-
6β), 2.68 (m, 1H, H-5β); 13C NMR (125 MHz, C5D5N): δ= 154.9 (C-9), 146.1 (C-2), 
145.9 (C-3), 135.9 (C-12a), 127.5 (CH-11), 124.9 (C-14a), 123.7 (C-8a), 122.9 (C-4a), 
119.6 (CH-12), 116.1 (CH-4), 113.6 (CH-1), 112.6 (CH-10), 59.6 (CH-14), 54.0 (CH-8), 
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 51.8 (CH2-6), 36.4 (CH2-13), 28.2 (CH2-5); MS (FAB) m/z (%): 284 [M+H]+, 164 (100); 
HRMS-FAB [M+H] + calcd for C17H18NO3: 284.1281, found: 284.1282. 
4.2.6.4. Synthesis of THP 6b by O-Debenzylation. A solution of 2,3-
dibenzyloxy-11-methoxy-THPB (6a) (200 mg, 0.419 mmol) was refluxed for 3 h in 
absolute EtOH (25 mL) and concentrated HCl (25 mL). The reaction mixture was 
evaporated to dryness, redissolved in CH2Cl2 (10 mL) and made basic (15% aqueous 
NH4OH). The organic solution was washed with brine (2 x 5 mL) and H2O (2 x 5 mL), 
dried with anhydrous Na2SO4, and evaporated to dryness. The crude product was 
purified by silica gel column chromatography (CH2Cl2/MeOH 95:5) to obtain the 2,3-
dihydroxy-11-methoxy-THPB (6b) (67 mg, 33%) as a yellow oil. 1H NMR (500 MHz, 
CDCl3): δ= 6.95 (d, J= 8.5 Hz, 1H, H-9), 6.70 (dd, J= 8.5, 2.4 Hz, 1H, H-10), 6.61 (d, 
J= 2.4 Hz, 1H, H-12), 6.51 (s, 1H, H-1), 6.20 (s, 3H, H-4, 2 x OH), 3.93 (d, J= 14.8 Hz, 
1H, H-8α), 3.73 (s, 3H, OCH3-11), 3.67 (d, J= 14.8 Hz, 1H, H-8β), 3.53 (dd, J= 11.2, 
3.4 Hz, 1H, H-14), 3.08 (dd, J= 16.7, 3.4 Hz, 1H, H-13α), 3.03 (m, 1H, H-6α), 2.90 (m, 
1H, H-5α), 2.76 (dd, J= 16.7, 11.2 Hz, 1H, H-13β), 2.57 (m, 1H, H-6β), 2.40 (m, 1H, H-
5β); 13C NMR (125 MHz, CDCl3): δ= 158.3 (C-11), 143.6 (C-3), 143.5 (C-2), 134.9 (C-
12a), 127.9 (C-14a), 127.1 (CH-9), 125.1 (C-4a), 124.9 (C-8a), 114.9 (CH-4), 113.5 
(CH-12), 112.5 (CH-10), 111.9 (CH-1), 59.0 (CH-14), 57.4 (CΗ2-8), 55.2 (OCH3-11), 
51.1 (CH2-6), 35.4 (CH2-13), 27.5 (CH2-5); MS (FAB) m/z (%): 298 [M+H]+, 164 (100); 
HRMS-FAB [M+H] + calcd for C18H20NO3: 298.1438, found: 298.1439. 
4.2.7. General procedure for the synthesis of THP 6c, 9e and 9f by formation 
of methylenedioxy group.  
4.2.7.1. 2,3-Methylenedioxy-11-methoxytetrahydroprotoberberine (6c). A 
solution of 2,3-dihydroxy-11-methoxy-THPB (6b) (100 mg, 0.34 mmol) in anhydrous 
DMF (3 mL) was treated with dichloromethane (10 mL, 155.6 mmol) and CsF (250 mg, 
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 1.64 mmol). The mixture was refluxed for 3 h with stirring. After cooling, the reaction 
mixture was extracted with CH2Cl2 and the organic layer was washed with 5% aqueous 
NaHCO3 and H2O, dried over with anhydrous Na2SO4 and concentrated in vacuo to 
dryness. The residue was purified by silica gel column chromatography (CH2Cl2/MeOH 
95:5) to obtain the 2,3-methylendioxy-11-methoxy-THPB (6c) (90 mg, 86%) as a 
yellow oil. 1H NMR (500 MHz, CDCl3): δ= 6.99 (d, J= 8.4 Hz, 1H, H-9), 6.74 (s, 1H, 
H-1), 6.72 (dd, J= 8.4, 2.5 Hz, 1H, H-10), 6.68 (d, J= 2.5 Hz, 1H, H-12), 6.59 (s, 1H, H-
4), 5.92 (s, 2H, OCH2O), 3.95 (d, J= 14.4 Hz, 1H, H-8α), 3.79 (s, 3H, OCH3-11), 3.65 
(d, J= 14.4 Hz, 1H, H-8β), 3.57 (dd, J= 11.2, 3.5 Hz, 1H, H-14), 3.25 (dd, J= 16.3, 3.5 
Hz, 1H, H-13α), 3.12 (m, 1H, H-6α), 3.09 (m, 1H, H-5α), 2.87 (dd, J= 16.3, 11.2 Hz, 
1H, H-13β), 2.63 (m, 1H, H-5β), 2.60 (m, 1H, H-6β); 13C NMR (125 MHz, CDCl3): δ= 
158.0 (C-11), 146.1 (C-2), 145.9 (C-3), 135.5 (C-12a), 130.8 (C-14a), 127.8 (C-4a), 
127.1 (CH-9), 126.6 (C-8a), 113.2 (CH-12), 112.3 (CH-10), 108.4 (CH-4), 105.5 (CH-
1), 100.7 (OCH2O), 59.8 (CH-14), 58.0 (CΗ2-8), 55.2 (OCH3-11), 51.3 (CH2-6), 37.2 
(CH2-13), 29.5 (CH2-5); MS (FAB) m/z (%): 310 [M+H]+, 176 (100); HRMS-FAB 
[M+H] + calcd for C19H20NO3: 310.1438, found: 310.1440. 
4.2.7.2. 2,3-Methylenedioxy-11-hydroxytetrahydroprotoberberine (9e). 2,3,11-
trihydroxy-THPB (9c) (100 mg, 0.353 mmol) was subjected to similar conditions to 
those above described to obtain the 2,3-methylenedioxy-11-hydroxy-THPB (9e). The 
residue was purified by silica gel column chromatography (CH2Cl2/ MeOH, 98:2), to 
obtain the THPB 9e (23 mg, 23%) as a white oil. 1H NMR (500 MHz, C5D5N): δ= 7.06 
(m, 3H, H-9, H-10, H-12), 6.90 (s, 1H, H-1), 6.63 (s, 1H, H-4), 5.96 (dd, J= 4.1, 1.2 Hz, 
2H, OCH2O), 4.00 (d, J= 14.3 Hz, 1H, H-8α), 3.62 (d, J= 14.3 Hz, 1H, H-8β), 3.57 (d, 
J= 11.4, 3.8 Hz, 1H, H-14), 3.33 (dd, J= 16.1, 3.8 Hz, 1H, H-13α), 3.12 (m, 1H, H-5α), 
3.04 (m, 1H, H-6α), 2.99 (dd, J= 16.1, 11.4 Hz, 1H, H-13β), 2.58 (m, 1H, H-5β), 2.54 
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 (m, 1H, H-6β); 13C NMR (125 MHz, C5D5N): δ= 157.4 (C-11), 146.7 (C-2), 146.5 (C-
3), 136.1 (C-12a), 131.3 (C-14a), 128.1 (C-4a), 127.5 (CH-9), 125.3 (C-8a), 115.8 (CH-
12), 114.6 (CH-10), 108.7 (CH-4), 106.5 (CH-1), 101.3 (OCH2O), 60.2 (CH-
14), 58.1 (CΗ2-8), 51.5 (CH2-6), 37.3 (CH2-13), 29.6 (CH2-5); MS (FAB) m/z (%): 296 
[M+H]+, 176 (100); HRMS-FAB [M+H] + calcd for C18H18NO3: 296.1281, found: 
296.1282. 
4.2.7.3. 2,3-Methylenedioxy-9-hydroxytetrahydroprotoberberine (9f). 2,3,9-
trihydroxy-THPB (9d) (100 mg, 0.353 mmol) was submitted to the same conditions 
depicted above to obtain the 2,3-methylenedioxy-9-hydroxy-THPB (9f). The residue 
was purified by silica gel column chromatography (CH2Cl2/ MeOH, 98:2), to obtain the 
THPB 9f (58 mg, 56%) as a white oil. 1H NMR (500 MHz, C5D5N): δ= 7.16 (t, J= 7.8 
Hz, 1H, H-11), 6.99 (d, J= 7.8 Hz, 1H, H-10), 6.95 (s, 1H, H-1), 6.84 (d, J= 7.8 Hz, 1H, 
H-12), 6.64 (s, 1H, H-4), 5.97 (dd, J= 4.9, 1.2 Hz, 1H, OCH2O), 4.55 (d, J= 15.6 Hz, 
1H, H-8α), 3.70 (d, J= 15.6 Hz, 1H, H-8β), 3.57 (dd, J= 11.1, 3.0 Hz, 1H, H-14), 3.38 
(dd, J= 15.9, 3.0 Hz, 1H, H-13α), 3.12 (m, 1H, H-6α), 3.06 (m, 1H, H-5α), 3.01 (dd, J= 
15.9, 11.1 Hz, 1H, H-13β), 2.54 (m, 1H, H-5β), 2.48 (m, 1H, H-6β); 13C NMR (125 
MHz, C5D5N): δ= 155.0 (C-9), 146.7 (C-2), 146.4 (C-3), 136.8 (C-12a), 131.8 (C-14a), 
128.4 (C-4a), 127.1 (CH-11), 123.1 (C-8a), 119.8 (CH-12), 112.5 (CH-10), 108.7 (CH-
4), 106.3 (CH-1), 101.2 (OCH2O), 59.9 (CH-14), 54.8 (CΗ2-8), 51.8 (CH2-6), 37.7 
(CH2-13), 29.9 (CH2-5); MS (FAB) m/z (%): 296 [M+H]+, 176 (100); HRMS-FAB 
[M+H] + calcd for C18H18NO3: 296.1281, found: 296.1280. 
4.3. Bioassays 
4.3.1. Binding experiments. These experiments were performed on striatal 
membranes. Each striatum was homogenized in 2 mL ice-cold Tris-HCl buffer (50 mM, 
pH = 7.4 at 22 ºC) with a Polytron (4s, maximal scale) and immediately diluted with 
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 Tris buffer. The homogenate was centrifuged either twice ([3H] SCH 23390 binding 
experiments) on four times ([3H] raclopride binding experiments) at 20000g for 10 min 
at 4 ºC with resuspension in the same volume of Tris buffer between centrifugations. For 
[3H] SCH 23390 binding experiments, the final pellet was resuspended in Tris buffer 
containing 5 mM MgSO4, 0.5 mM EDTA and 0.02% ascorbic acid (Tris-Mg buffer), 
and the suspension was briefly sonicated and diluted to a protein concentration of 1 
mg/mL. A 100µL aliquot of freshly prepared membrane suspension (100 µg of striatal 
protein) was incubated for 1h at 25 ºC with 100µL Tris buffer containing [3H] SCH 
23390 (0.25 nM final concentration) and 800µL of Tris-Mg buffer containing the 
required drugs. Non-specific binding was determined in the presence of 30 µM SK&F 
38393 and represented around 2-3% of total binding. For [3H] raclopride binding 
experiments, the final pellet was resuspended in Tris buffer containing 120 mM NaCl, 5 
mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 0.1% ascorbic acid (Tris-ions buffer), and the 
suspension was treated as described above. A 200 µL aliquot of freshly prepared 
membrane suspension (200 µg of striatal protein) was incubated for 1 h at 25 °C with 
200 µL of Tris buffer containing [3H] raclopride (0.5 nM, final concentration) and 400 
µL of Tris-ions buffer containing the drug under investigation. Non-specific binding was 
determined in the presence of 50 µM apomorphine and represented around 5-7% of the 
total binding. In both cases, incubations were stopped by addition of 3 mL of ice-cold 
buffer (Tris-Mg buffer or Tris-ions buffer, as appropriate) followed by rapid filtration 
through Whatman GF/B filters. Tubes were rinsed with 3 mL of ice-cold buffer, and 
filters were washed with 3 x 3 mL ice-cold buffer. After the filters had been dried, 
radioactivity was counted in 4 mL BCS scintillation liquid at an efficiency of 45%. 
Filter blanks corresponded to approximately 0.5% of total binding and were not 
modified by drugs.  
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 4.3.2. In vitro cytotoxicity studies. Cytotoxicity of the THPBs was studied by the 
use of two different in vitro approaches (MTT colorimetric assay and flow cytrometry 
analysis) [42]. Cytotoxicity was evaluated on freshly isolated human peripheral blood 
neutrophils. Human neutrophils were obtained from buffy coats of healthy donors by 
Ficoll-Hypaque density gradient centrifugation, as previously described [43]. Cultures 
were maintained at 37 ºC under 5% CO2 and 95% air atmosphere in RPMI-1640 
medium (Sigma–Aldrich Chemical, USA). 
4.3.2.1. MTT assay. The viability of neutrophils was determined using the 
previously described MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) colorimetric assay [44]. In this assay, the yellow MTT is reduced to a blue 
formazan product by the mitochondria of viable cells. MTT (Sigma–Aldrich) was 
prepared at 1 mg/mL in RPMI and stored at 4 ºC in the dark. 100 µl of neutrophils 
suspension (2 x 105 cells/mL) was added to each well of a 96-well microtiter plate 
followed by 20 µl of the appropriate concentration of the THPBs tested. The mixture 
was incubated at 37 ºC for 24 h. Then, 100 µl aliquot of MTT solution was added to 
each well and incubated at 37°C for another 60 min. The supernatants were discarded 
and 100 µl of DMSO was added to each well to dissolve the precipitated formazan. The 
optical densities at dual wavelengths (570 and 630 nm) were determined in a 
spectrophotometer (Infinite M200, Tecan, Mannedorf, Switzerland). 
4.3.2.2. Cytofluorometric Analysis of Neutrophil Apoptosis and Survival. 
Freshly isolated neutrophils were resuspended in supplemented RPMI medium at 2 x 106 
cells/mL. 25 µl were cultured in a 24-well plate containing 200 µl of supplemented 
RPMI medium for 24 h in the absence or presence of the most active THPBs on D2 DR 
(6b, 9d and 9f). Assessment of apoptosis was performed by flow cytometry using 
annexin V- FITC and propidium iodide (PI). The protocol indicated by the manufacturer 
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 (Annexin- Fluos; Roche Applied Science) was used as outlined previously [45]. Cells (1 
x 104) were analyzed in a Beckman Coulter Epics XL (Fullerton, CA) and differentiated 
as early or viable apoptotic (annexin V+ and PI-), late apoptotic and/or necrotic (annexin 
V+ and PI+), and viable nonapoptotic (annexin V- and PI-) cells.  
4.4. Molecular Modeling 
4.4.1. Molecular dynamics simulations of complexes. A 3D model of the human 
D2 DR was used for the MD simulations. This model is based on the homology model 
from the crystallized D3 DR, β2 adrenoceptor and Α2α adenosine receptor as templates 
[46].  
(PMDB: http://mi.caspur.it/PMDB/codes: PM0077430). 
The complex geometries from docking were soaked in boxes of explicit water 
using the TIP3P model [47] and subjected to MD simulation. All MD simulations were 
performed with the Amber software package using periodic boundary conditions and 
cubic simulation cells. The particle mesh Ewald method (PME) [48] was applied using a 
grid spacing of 1.2 Å, a spline interpolation order of 4 and a real space direct sum cutoff 
of 10 Å. The SHAKE algorithm was applied allowing for an integration time step of 2 
fs. MD simulations were carried out at 300 K target temperature and extended to 10 ns 
overall simulation time. The NPT ensemble was employed using Berendsen coupling to 
a baro/thermostat (target pressure 1 atm, relaxation time 0.1 ps). Post MD analysis was 
carried out with program PTRAJ. 
4.4.2. MM-GBSA free energy decomposition. In order to determine the residues 
of the D2 DR active site involved in the interactions, the residues proposed by Andujar et 
al. [17] and Soriano-Ursua et al. were first identified. Then MM-GBSA free energy 
decomposition using the mm_pbsa program in AMBER12 was employed to corroborate 
the amino acids interacting with the ligands. This calculation can decompose the 
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 interaction energies of each residue considering molecular mechanics and solvation 
energies [49,50]. Each ligand–residue pair includes four energy terms: van der Waals 
contribution (Evdw), electrostatic contribution (Eele), polar desolvation term (GGB) and 
nonpolar desolvation term (GSA), which are summarized in the following equation: 
ΔGinhibitor-residue= ΔEvdW + ΔEele + ΔGGB + ΔGSA 
For MM-GBSA methodology, snapshots were taken at 10 ps time intervals from 
the corresponding last 1000 ps MD trajectories and the explicit water molecules were 
removed from the snapshots. 
4.4.3. Quantum mechanics calculations and topological study of the electron 
charge density distribution. 19 amino acids were included in this reduced model based 
on the generated data. Three molecular complexes, 9d/D2DR, 9c/D2DR and 6b/D2DR, 
obtained for our “reduced model system”, were selected due to their reprensentative 
chemical feautures for the calculation of the charge density. Single point calculations 
were performed with Gaussian 03 and employing a hybrid B3LYP functional and 6-
31G(d) as basis set. This type of calculation has been recently used in studies on the 
topology of (r) because it ensures a reasonable compromise between the wave function 
quality required to obtain reliable values of the derivatives of (r) and the computer power 
available, due to the extension of the system in study [17,18]. The topological properties 
of a scalar field such as (r) are summarized in terms of their critical points, i.e., the points 
rc where (r) = 0. Critical points are classified according to their type (,) by stating their 
rank, and signature. The rank is equal to the number of nonzero eigenvalues of the 
Hessian matrix of (r) at rc, while the signature is the algebraic sum of the signs of the 
eigenvalues of this matrix. Critical points of (3, -1) and (3, +1) type describe saddle 
points, where the (3, -3) is the maximum and (3, +3) is the minimum in the field. Among 
these critical points, the (3,-1) or bond critical points are the most relevant ones since 
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 they are found between any two atoms linked by a chemical bond. The determination of 
all the bond critical points and the corresponding bond paths connecting these point with 
bonded nuclei, were performed with the AIMAll software. The molecular graphs were 
drafted using the same program. Spatial views shown in Figures 10 and 11 were 
constructed using the UCSF Chimera program as graphic interface. 
It should be noted that the THPBs here reported were enantiomeric, they possessed 
one chiral center and they could raise two isomers (S and R). However, although an 
enantiomeric resolution for the biological assays was not carried out, only one isomer of 
each compound was evaluated in the calculations. The isomeric forms selected were first 
chosen on the basis of previously reported results [8-14] and on the exploratory 
simulations in which the spatially preferred form for these compounds was determined 
(results not shown). In this context, Sun et al. [23] showed that when a substituition was 
performed at the D ring, the S-isomers of THPBs displayed stronger affinities for the D2 
DR than their corresponding R-isomer. In addition, previous experimental findings with 
BTHIQs also supported this hypothesis since S forms were the preferred conformation 
of these compounds [13].  Finally, the preliminary and exploratory MD simulations 
peformed for the THPBs here synthesized revealed that the ∆∆G values obtained for the 
R-isomers are at least 10 Kcal/mol higher than their respective S-isomers. Therefore, the 
spatial conformationg adopted by the S forms seemed to provide the adequate 
orientation of the molecules for their interaction with the active site at the D2 DR. 
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 Figure captions 
 
Figure 1. THPBs series. 
Figure 2. Displacement curves of [3H]-SCH 23390 (D1) and [3H] raclopride (D2) specific 
binding by compounds 9d and 9f. Data were displayed as mean ± SEM for 3-5 experiments. 
 
Figure 3. Displacement curves of the specific binding of D1 and D2 DR ligands by the 
compounds 9e and 9f. Data were displayed as mean ± SEM for 3-5 experiments. 
 
Figure 4. Displacement curves of the specific binding of D1 and D2 DR ligands by the 
compounds 6b and 9c. Data were displayed as mean ± SEM for 3-5 experiments. 
 
Figure 5. Effect of the synthesized THPBs on viability of human neutrophils. Data are 
presented as mean ± SEM of n=3 independent experiments. 
 
Figure 6. Percentage of apoptotic (A) and survival cells (B) after incubation with THPBs 6b, 9d 
and 9f. Early apoptotic cells were quantified as the percentage of total population of annexin 
V+,PI− cells, late apoptotic, and/or necrotic cells as annexin V+ and PI+, and viable 
nonapoptotic cells as annexin V− and PI− at 24 h of culture of human neutrophils. The columns 
are the means ± SEM of n=3 independent experiments. Representative flow cytometry panels 
showing the effects of compounds 6b, 9d and 9f on human neutrophil apoptosis have been 
included. 
 
Figure 7. Spatial view of compound 9d (green)/D2DR interaction. Magnification of the receptor 
active site at the right. 
 
Figure 8. Histograms of interaction energies partitioned for D2 DR amino acids when 
complexed with compound 9d (a), compound 9c (b) and compound 6b (c). The x-axis denotes 
the residue number of D2 DR, and the y-axis shows the interaction energy between the 
compound and the specific residue. Negative and positive values represent favourable or 
unfavourable binding, respectively. 
 
Figure 9. Spatial view of the active D2 DR site for compounds 9d (a), 9c (b) and 6b (c).  
The names of the residues involved in the main interactions are written in the figure. 
 
Figure 10. Molecular graph of compound 9d interaction with the binding site. Large spheres 
represent attractors or nuclear critical points (3, -3) attributed to the atomic nuclei. The 
connecting nuclei lines are bond paths and small spheres on them are bond critical points (3, -1). 
 
Figure 11. Molecular graph of compound 9c interaction with the binding site. The interactions 
for the catecholic hydroxyls are shown in (a) and the interactions of OH-11 are shown in (b). 
 
Figure 12. Molecular graph for compound 6b interaction at the binding site. The interactions for 
the catecholic hydroxyls are shown in (a) and the interactions of OMe-11 are shown in (b). 
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 Scheme 1. Synthesis of THPBs 3a and 3b (Series 1). Reagents and Conditions: (a) 
Nitromethane, NH4OAc, AcOH, reflux, 4h; (b) LiAlH4, THF / Et2O, N2, reflux, 2h; (c) CH2Cl2, 
3-methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (d) P2O5, POCl3, Toluene, N2, reflux, 8h; (e) 
NaBH4; MeOH, rt, 2h; (f) HCHO, EtOH, H2O, reflux, 5h; (g) CH2Cl2, BBr3, rt, 2h. 
 
 
Scheme 2. Synthesis of THPBs 6a-6c (Series 2). Reagents and Conditions: (a) Benzyl chloride, 
K2CO3, EtOH, reflux, 6h; (b) Nitromethane, NH4OAc, AcOH, reflux, 4h; (c) LiAlH4, THF / 
Et2O, N2, reflux, 2h; (d) CH2Cl2, 3-methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (e) POCl3, 
CH3CN, N2, reflux, 5h; (f) NaBH4; MeOH, rt, 2h; (g) 37% HCHO, EtOH, H2O, reflux, 5h; (h) 
EtOH-HCl, reflux, 3h; (i) DMF, CH2Cl2, CsF, reflux, 3h. 
 
Scheme 3. Synthesis of THPBs 9a-9f (Series 3). Reagents and Conditions: (a) CH2Cl2, 3-
methoxyphenylacetyl chloride, 5% NaOH, rt, 3h; (b) POCl3, CH3CN, N2, reflux, 5h; and, 
NaBH4, MeOH, rt, 2h; (c) HCHO, EtOH, H2O, reflux, 5h; (d) CH2Cl2, BBr3, rt, 2h; (e) DMF, 
CH2Cl2, CsF, reflux, 3h. 
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